Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ETON vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ETON Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

ETON Overall Winner 6-Pillar Tally: ETON 6 – 0 DMAC Matrix Metrics: ETON 8 – 2 DMAC

As of Nov 16, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ETON carries a Unified Composite Score of 36.5/100 (SELL) at $64.30 (19.3x Forward P/E, 31.3% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While DMAC currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. ETON 36.5/100 SELL), ETON captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (31.3% vs. 0.0% operating margin) and revenue trajectory (+157.9% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ETON vs DMAC
ETON NASDAQ Head-to-Head Winner
Eton Pharmaceutcials, Inc. Common Stock
Pharmaceutical Preparations
$64.30
+0.58% 1D
Market Cap $1.8B
TTM Revenue $141M
Forward P/E 19.3x
Beta / 30D Vol 0.63β · 99% Vol
Unified Composite Score
36.5 / 100 SELL
Tech 50.0 Fund 36.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 62.3 · SMA20: $55.23 · SMA50: $55.38
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (ETON 6 – 0 DMAC)

Columns: Metric · ETON · DMAC
1. Valuation Multiples ETON
Forward P/E 19.3x N/M
Trailing P/E 39.9x N/M
PEG Ratio N/M N/M
EV / Revenue 12.3x N/M
2. Growth & Scale ETON
Revenue Growth (YoY) +157.9% +0.0%
Earnings Growth (YoY) -12.6% +0.0%
TTM Revenue (USD) $141M N/A
Market Cap $1.8B $503.1M
3. Profitability & Quality ETON
Gross Margin 71.2% N/A
Operating Margin 31.3% 0.0%
Net Profit Margin 35.4% 0.0%
Return on Equity (ROE) 90.6% -114.6%
4. Balance Sheet & Cash Flow ETON
Cash Generation (TTM) $20M -$32M
Cash Flow Margin 14.2% N/A
Net Cash / Leverage $32M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ETON
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 59.3% (14th %ile) 106.3% (14th %ile)
Put/Call OI Skew 0.13x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ETON
OpEx & R&D Intensity 39.9% of Rev ($56M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ETON (8) vs DMAC (2)
Institutional Metric ETON DMAC Criterion Row Edge
Market Capitalization
Scale
$1.8B $503.1M Larger Scale ETON
Trailing P/E Ratio
Valuation
39.9x N/M Lower Multiple ETON
Forward P/E Ratio
Valuation
19.3x N/M Lower Multiple ETON
Revenue Growth (YoY)
Growth
+157.9% +0.0% Higher Growth ETON
Operating Margin (TTM)
Profitability
31.3% 0.0% Higher Margin ETON
Net Profit Margin
Profitability
35.4% 0.0% Higher Margin ETON
Return on Equity (ROE)
Capital Efficiency
90.6% -114.6% Higher ROE ETON
52-Week Range Position
Momentum
89% ($14–$71) 55% ($5–$11) Stronger Trend ETON
Beta / 30D Volatility
Risk Regime
0.63β · 99% Vol 1.74β · 98% Vol Lower Realized Risk DMAC
Unified Institutional Score
Composite Signal
36.5 / 100 (SELL) 46.3 / 100 (HOLD) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
$141M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 12.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($32M Net Cash) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ETON +16.65 pp
ETON: +27.81% · DMAC: +11.16%
3M Horizon DMAC +25.94 pp
ETON: +1.37% · DMAC: +27.31%
6M Horizon ETON +49.76 pp
ETON: +97.91% · DMAC: +48.15%
1Y Horizon ETON +225.66 pp
ETON: +280.92% · DMAC: +55.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ETON Revenue DMAC Revenue ETON Op. Margin DMAC Op. Margin Margin Leader
FY2018 N/A $0M N/A -1352.2% DMAC
FY2019 $0M N/A -1939.6% N/A ETON
FY2020 $0M N/A -69515.4% N/A ETON
FY2021 $20M N/A -6.8% N/A ETON
FY2022 $20M N/A -38.9% N/A ETON
FY2023 $30M N/A -3.8% N/A ETON
FY2024 $40M N/A -6.7% N/A ETON
FY2025 $80M N/A -1.1% N/A ETON

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ETON CONSOLIDATION
59d in phase · OBV ACCUMULATION
Current IV 59.3%
IV Percentile 14th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ETON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ETON Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.8B market capitalization and 31.3% operating margin.
OpEx & R&D Reinvestment 39.9% of Rev ($56M)
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ETON vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ETON carries a Unified Composite Score of 36.5/100 (SELL) at $64.30 (19.3x Forward P/E, 31.3% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DMAC currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. ETON 36.5/100 SELL), ETON captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (31.3% vs. 0.0% operating margin) and revenue trajectory (+157.9% vs. +0.0% YoY).

ETON leads the Growth & Scale pillar: ETON posts +157.9% YoY revenue growth and -12.6% YoY earnings growth on $141M TTM revenue (71.2% gross margin, 31.3% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ETON cumulative revenue shifted +300.0% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, ETON deploys 39.9% of Rev ($56M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

ETON screens cheaper on headline valuation multiples. ETON trades at 19.3x Forward P/E, 39.9x Trailing P/E, N/M PEG, and 12.3x EV/Revenue (14.2% FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ETON (90.6% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ETON carries 59.3% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.63β · 99% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.